Journal of Oncology Translational Research



Analysis of FNA findings of Salivary gland lesions using Milan System of Reporting salivary gland cytopathology(MSRSGC) in a tertiary care institute in South India

Rohit Kotipalli and Nandini.N.M

JSS Medical College and Hospital, India

Abstract

Aims and Objectives – The Milan System for reporting Salivary Gland Cytopathology is a internationally accepted reporting system for preoperative diagnosis and management of salivary gland lesions. The MSRSGC has the following 6 diagnostic categories: 1) Nondiagnostic, 2) Non-neoplastic, 3) Atypia of undetermined significance, 4) Neoplasm (further divided as benign and salivary gland neoplasm of uncertain malignant potential), 5) Suspicious for malignancy, and 6) malignant. The aim of the study is to analyse various salivary gland lesions and classify them as per MSRSGC. Correlation with histopathological findings will be done wherever possible.

Methods - Retrospective study over a period of 2 years (2019 to 2020). The FNA aspirates of salivary gland lesions will be ennumerated and classified according to MSRSGC. Each case will be reviewed by two pathologists two avoid any inter observer bias.

Results- All the cases studied over 2 years will be studied and subtyped and results will be analysed.

Conclusion- MSRSGC will help classifying both neoplastic and non-neoplastic salivary gland lesions into accurate groups and helps to redefine the grey zone lesions on cytology. This will help the surgeons to better plan the further management.

Biography

Rohit Kotipalli has completed his MBBS at the age of 24 from Dr.NTRUHS and is presently pursuing postdoctoral studies from JSS medical college and hospital, a constituent of JSSAHER, mysore, India.



21st Global Summit on Breast Cancer February 26, 2021

Citation: Rohit Kotipalli, Analysis of FNA findings of Salivary gland lesions using Milan System of Reporting salivary gland cytopathology(MSRSGC) in a tertiary care institute in South India, Breast Cancer Meet 2021, 20th Global Summit on Breast Cancer, February 26, 2021, and Page No-04